Skip to main content
. 2017 Sep 29;7:12432. doi: 10.1038/s41598-017-12810-9

Figure 3.

Figure 3

Motor behavioral consequences of nigrostriatal DA depletion. (A) Mean total distance (cm) measured at 5-min interval for 2 hrs every 4 weeks before and after AAV2-GFP or AAV2-CRE-GFP bilateral injection in VMAT2lox/lox mice (n = 7 per groups; Mann-Whitney U: AAV2-GFP vs AAV2-CRE-GFP: week 8 to 16 *p < 0.05). (B) Mean latency to fall (s) in the accelerating rotarod over 4 consecutive sessions (4 to 25 rpm) every 4 weeks before and after AAV2-GFP (n = 8) or AAV2-CRE-GFP (n = 7) bilateral injection in VMAT2lox/lox mice (Mann-Whitney U: AAV2-GFP vs AAV2-CRE-GFP: week 8 *p < 0.05; week 12 *p < 0.05; week 16 **p < 0.01). (C) Latency to fall (s) in the grip test 16 weeks’ post- bilateral injection of AAV2-GFP or AAV2-CRE-GFP in VMAT2lox/lox mice. Mann-Whitney U: AAV2-GFP vs AAV2-CRE-GFP: p = 0.73). (D) Gait analysis parameters in VMAT2lox/lox mice 8 and 16 weeks’ post AAV2-GFP or AAV2-CRE-GFP bilateral injection. Stride length (cm), stance width (cm) and paw angle (°). No differences in gait at 8 weeks’ post-injection (Mann-Whitney U: AAV2-GFP vs AAV2-CRE-GFP: Length p = 0.11; width p = 0.90; Angle p = 0.93). Change the coordination of ambulation in AAV2-CRE-GFP injected mice compared to AAV2-GFP at 16 weeks’ post-injection (Mann-Whitney U: AAV2-GFP vs AAV2-CRE-GFP: Length *p < 0.05; width p = 0.75; Angle **p < 0.01). VMAT2: Vesicular Monoamine Transporter-2, AAV: Adenoassociated Virus.